Lifeward Ltd. (NASDAQ: LFWD)

ReWalk Robotics Ltd., a medical device company with the ticker symbol LFWD, operates in the physical rehabilitation and recovery industry. The company's main business activities revolve around designing, developing, and commercializing life-changing solutions that cater to the continuum of care in physical rehabilitation and recovery. ReWalk has initially offered the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices, targeted at individuals with spinal cord injuries (SCI). These devices are robotic exoskeletons driven by patented tilt-sensor technology, onboard computers, and motion sensors, enabling SCI individuals to stand and walk during everyday activities at home or in the community.

ReWalk's primary products, the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices, generate revenue through sales mainly in the United States and Europe, with some presence in Asia, the Middle East, and South America. The ReWalk Personal Exoskeleton is designed for daily use, consisting of a wearable exoskeleton, integrated motors, an array of sensors, and a computer-based control system. This device allows individuals with SCI to control movements using subtle weight shifts of the upper body and user inputs on a wrist-worn controller. The ReWalk Rehabilitation Exoskeleton is substantially similar but sold with adjustable parts for multiple users in a clinical setting, providing valuable exercise, training, and therapy.

ReWalk competes in the industry with key competitors such as Ekso Bionics, Rex Bionics, Cyberdyne, FREE Bionics, DIH, Wandercraft, and Bioness. The company's competitive advantage lies in its SCI Products, which may reduce the lifetime healthcare costs of individuals with spinal cord injuries, making them economically attractive for individuals and third-party payors. ReWalk's customers include individuals with SCI, rehabilitation centers, hospitals, and other healthcare providers.

The company's product range extends beyond the ReWalk devices. ReWalk's AlterG Anti-Gravity system is a series of products using partial weight-bearing technology for lower extremity rehabilitation. The system offers the FIT, VIA, and PRO models, marketed and sold directly to rehabilitation centers, hospitals, and other healthcare providers. Additionally, ReWalk's ReStore Exo-Suit, a soft, fabric-based exoskeleton, targets stroke patients, offering mechanical assistance during forward propulsion and ground clearance. This product has received FDA and CE clearance and is commercially available in the United States and Germany.

ReWalk faces extensive regulatory requirements in the United States and abroad. In the U.S., the company's products are regulated by the FDA, requiring clearance or approval before marketing. Products must undergo safety and effectiveness evaluations during the premarket notification or premarket approval application process. Post-market regulatory requirements include establishment registration, quality assurance system, labeling, and medical device reporting requirements. Non-compliance may result in enforcement actions, fines, injunctions, or even product withdrawal.

Similarly, ReWalk's products are subject to regulation outside the United States, including in the European Union under the MDR, the United Kingdom, Canada, Australia, and Japan. Each jurisdiction requires approval from the relevant regulatory authorities before marketing the company's products.